Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
Josée Golay, Ronald P. Taylor
Antibodies (2020) Vol. 9, Iss. 4, pp. 58-58
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Mechanisms of Therapeutic Antitumor Monoclonal Antibodies
Li-Chung Tsao, Jeremy Force, Zachary C. Hartman
Cancer Research (2021) Vol. 81, Iss. 18, pp. 4641-4651
Open Access | Times Cited: 142
Advances in antibody-based therapy in oncology
Sacha Zinn, Rodrigo Vazquez-Lombardi, Carsten Zimmermann, et al.
Nature Cancer (2023) Vol. 4, Iss. 2, pp. 165-180
Closed Access | Times Cited: 119
A guide to complement biology, pathology and therapeutic opportunity
Dimitrios C. Mastellos, George Hajishengallis, John D. Lambris
Nature reviews. Immunology (2023) Vol. 24, Iss. 2, pp. 118-141
Closed Access | Times Cited: 101
Cancer therapy with antibodies
Suman Paul, Maximilian F. Konig, Drew M. Pardoll, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 6, pp. 399-426
Closed Access | Times Cited: 45
Complement regulators as novel targets for anti-cancer therapy: A comprehensive review
Ruchi Saxena, Elizabeth B. Gottlin, Michael J. Campa, et al.
Seminars in Immunology (2025) Vol. 77, pp. 101931-101931
Closed Access | Times Cited: 2
Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies
Josée Golay, Alain E. Andrea, Irene Cattaneo
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 51
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
Xavier Leleu, Thomas G. Martin, Katja Weisel, et al.
Annals of Hematology (2022) Vol. 101, Iss. 10, pp. 2123-2137
Open Access | Times Cited: 47
Emerging Trends in Immunotherapy for Cancer
Alok Mishra, Amjad Ali, Shubham Dutta, et al.
Diseases (2022) Vol. 10, Iss. 3, pp. 60-60
Open Access | Times Cited: 46
Mechanisms of Action and Limitations of Monoclonal Antibodies and Single Chain Fragment Variable (scFv) in the Treatment of Cancer
Cynthia Rodríguez-Nava, Carlos Ortuño‐Pineda, Berenice Illades‐Aguiar, et al.
Biomedicines (2023) Vol. 11, Iss. 6, pp. 1610-1610
Open Access | Times Cited: 28
Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies
Takao Arimori, Emiko Mihara, Hiroyuki Suzuki, et al.
Structure (2024) Vol. 32, Iss. 5, pp. 536-549.e5
Closed Access | Times Cited: 14
GD2-targeting therapy: a comparative analysis of approaches and promising directions
Julia Philippova, Julia Shevchenko, С. В. Сенников
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 12
Combination Therapy as a Promising Way to Fight Oral Cancer
João P. N. Silva, Bárbara Pinto, Luı́s Monteiro, et al.
Pharmaceutics (2023) Vol. 15, Iss. 6, pp. 1653-1653
Open Access | Times Cited: 19
Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope
Alejandrina Hernández-López, Mario A. Téllez-González, Paul Mondragón‐Terán, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 37
Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis
Li-Chung Tsao, Erika J. Crosby, Timothy N. Trotter, et al.
JCI Insight (2022) Vol. 7, Iss. 6
Open Access | Times Cited: 27
Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment
Silvia Delgado, Simon Faissner, Ralf A. Linker, et al.
Journal of Neurology (2023) Vol. 271, Iss. 4, pp. 1515-1535
Open Access | Times Cited: 14
Antitumor activities of anti‑CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer
Kenichiro Ishikawa, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
Oncology Reports (2024) Vol. 52, Iss. 5
Open Access | Times Cited: 5
The immunological processes behind aquaporin 4-antibody seropositive neuromyelitis optica spectrum disorders
Monika Bradl, Qian Yu, Yoshiki Takai
Seminars in Immunology (2025) Vol. 78, pp. 101945-101945
Open Access
Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions
Yu Tang, Yanguang Cao
Pharmaceutics (2021) Vol. 13, Iss. 3, pp. 422-422
Open Access | Times Cited: 27
Strategies to enhance monoclonal antibody uptake and distribution in solid tumors
Brandon M. Bordeau, Joseph P. Balthasar
Cancer Biology and Medicine (2021) Vol. 18, Iss. 3, pp. 649-664
Open Access | Times Cited: 27
Diverse Functions of C4b-Binding Protein in Health and Disease
Lacie M. Werner, Alison K. Criss
The Journal of Immunology (2023) Vol. 211, Iss. 10, pp. 1443-1449
Closed Access | Times Cited: 12
Complement‐targeted therapeutics: Are we there yet, or just getting started?
Daniel Ricklin
European Journal of Immunology (2024) Vol. 54, Iss. 12
Open Access | Times Cited: 4
The role of complement in tumor immune tolerance and drug resistance: a double-edged sword
Ronghui Yang, Di Fu, Aijun Liao
Frontiers in Immunology (2025) Vol. 16
Open Access
Locally Misfolded HER2 Expressed on Cancer Cells is a Promising Target for Development of Cancer-Specific Antibodies
Takao Arimori, Emiko Mihara, Hiroyuki Suzuki, et al.
(2023)
Closed Access | Times Cited: 9
Overview of tumor immunotherapy based on approved drugs
Ziqin Chen, Tiantian Hu, Jing Zhou, et al.
Life Sciences (2024) Vol. 340, pp. 122419-122419
Closed Access | Times Cited: 3
Anti-HER2 cancer-specific mAb, H2Mab-250-hG<sub>1</sub> possesses higher complement-dependent cytotoxicity than trastuzumab
Hiroyuki Suzuki, Tomokazu Ohishi, Tomohiro Tanaka, et al.
(2024)
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top